In the developed world colic is a leading cause of euthanasia in horses, making it a highly significant welfare issue and cause of financial loss to the equine industry. A reduction in the morbidity and mortality associated with colic and other diseases where endotoxaemia results will be extremely important.
This study has identified a drug which effectively inhibits inflammatory cell activation and cytokine production in experimental horses in response to an endotoxin challenge. This drug has the potential to be a very useful addition to the current therapies available for the treatment of colic and endotoxaemia.